Atara Biotherap (ATRA) Stock Price, Quote & News

Latest News on ATRA

Mar 7, 2025, 4:01 PM EST - 7 weeks ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 1, 2025, 11:00 AM EST - 2 months ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 2 months ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 14, 2025, 8:11 AM EST - 2 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 11, 2025, 7:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 2 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 9, 2025, 7:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 7, 2025, 4:01 PM EST - 2 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 7:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 6, 2025, 7:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 5, 2025, 7:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 4, 2025, 7:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 3, 2025, 11:00 AM EST - 3 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 7:00 AM EST - 3 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 30, 2025, 7:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 29, 2025, 7:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 28, 2025, 11:00 AM EST - 3 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 7:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

Jan 28, 2025, 3:23 AM EST - 3 months ago

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Jan 27, 2025, 8:30 PM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Jan 21, 2025, 1:11 PM EST - 3 months ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Jan 21, 2025, 7:30 AM EST - 3 months ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Jan 21, 2025, 12:21 AM EST - 3 months ago

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 16, 2025, 8:41 AM EST - 3 months ago

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Jan 16, 2025, 8:30 AM EST - 3 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Nov 27, 2024, 4:01 PM EST - 5 months ago

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Nov 13, 2024, 4:01 PM EST - 5 months ago

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:01 PM EST - 5 months ago

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Nov 5, 2024, 4:01 PM EST - 6 months ago

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Sep 4, 2024, 4:01 PM EDT - 8 months ago

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:16 PM EDT - 8 months ago

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Aug 12, 2024, 5:00 PM EDT - 9 months ago

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Aug 7, 2024, 4:01 PM EDT - 9 months ago

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 9:00 AM EDT - 10 months ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 3, 2024, 7:57 PM EDT - 10 months ago

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Jul 3, 2024, 1:39 PM EDT - 10 months ago

Market Cap	32.75M
Revenue (ttm)	128.94M
Net Income (ttm)	-85.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-66.23%
Debt to Equity Ratio	0.00

Volume	30,500
Avg Vol	58,394
Day's Range	N/A - N/A
Shares Out	5.86M
Stochastic %K	81%
Beta	0.32
Analysts	Sell
Price Target	$13.25